A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

Part of paid clinical trials in San Antonio, Texas.

Sponsor: Ascletis Pharma (China) Co., Limited
Study ID: NCT06972992
Phase: PHASE1
Status: Completed

Conditions

Chronic Weight Management

Eligibility Criteria

Sex: ALL
Age: 18 Years - 65 Years
Healthy Volunteers: Accepted

Interventions

ASC47 +Semaglutide — DRUG
ASC47 single subcutaneous injection + Semaglutide QW for 4 weeks
Placebo+Semaglutide — DRUG
Placebo single subcutaneous injection + Semaglutide QW for 4 weeks

Study Details

This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.

Key Dates

Start date: Apr 18, 2025
Status verified: Sep 2025
Primary completion: Sep 22, 2025
Completion: Sep 22, 2025

Study Design

Enrollment: 28 participants (actual)
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Arms

Experimental: Combo Cohort 1 in participants with obesity
Cohort 1, dose 1
Experimental: Combo Cohort 2 in participants with obesity
Cohort 2, dose 2
Experimental: Combo Cohort 3 in participants with obesity
Cohort 3, dose 3

Primary Outcome Measure

Adverse events [ Time Frame: up to 71 days ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Ascletis Clinical Site	San Antonio	Texas	78209	-

Find similar trials in San Antonio, TX

By research site

Ascletis Clinical Site· San Antonio, TX